JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet

 
• By Reed Miller and Marion Webb

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.

J.P. Morgan Daily Notebook 2022 Day 2
• Source: Alamy

Abbott expects demand for its rapid COVID-19 tests to remain high through at least 2022, even if the current Omicron surge recedes.

During a “fireside chat” at the J.P

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business